Opfolda Alternatives Compared
Opfolda | Nexviazyme | Lumizyme |
|
---|
Opfolda (miglustat) | Nexviazyme (avalglucosidase alfa) | Lumizyme (alglucosidase alfa) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Pompe Disease. Opfolda may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pompe Disease. Nexviazyme may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Pompe Disease. Lumizyme may also be used for purposes not listed in this medication guide. |
Related suggestions |
|||||||||||||||||||||||
More about Opfolda (miglustat) | More about Nexviazyme (avalglucosidase alfa) | More about Lumizyme (alglucosidase alfa) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: Opfolda side effects in more detail. |
See also: Nexviazyme side effects in more detail. |
See also: Lumizyme side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Opfolda prices |
View all Nexviazyme prices |
View all Lumizyme prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other miglustat brands include: Yargesa, Zavesca |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
7 hours |
1.6 hours |
3.4 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
Myozyme
Category C
Risk cannot be ruled out
Lumizyme See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 1 drugs are known to interact with Opfolda:
|
A total of 1 drugs are known to interact with Nexviazyme:
|
A total of 1 drugs are known to interact with Lumizyme:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
September 28, 2023 |
N/A |
May 24, 2010 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.